Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004364 (
autoimmune disease
)
24,845
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Primary biliary cirrhosis (PBC) is considered an
autoimmune disease
characterized by destruction of small intrahepatic bile ducts by lymphocytes. Altered functions of these lymphocytes might reflect an abnormal immune response leading to tissue damage. We investigated lymphokine secretion by mitogen-stimulated T lymphocytes from the liver biopsies of patients with PBC and for comparison also peripheral blood. In PBC, diminished synthesis of lymphotoxin (TNF beta), tumor necrosis factor (TNF alpha) and interferon-gamma (
IFN
gamma) was found both in T-cell lines from liver tissue and in peripheral blood. The reduction was most prominent for TNF beta in early histological stages of PBC, and appeared to be a stable phenomenon when T cells were tested after long-term tissue culture. Analysis of mRNA levels indicates a possible link between reduced TNF beta production and a defect in interleukin-2 transcription. The data suggest that diminished lymphokine production in patients with PBC may play an important role in the immunopathogenesis of this disease.
...
PMID:T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation. 150 29
During infection with L.monocytogenes, a facultative intracellular bacteria, TcR gamma/delta T cells specific for 65 kd hsp precede TcR alpha/beta T cells specific for the listerial antigens in appearance. The gamma/delta T cells provide a first line of defense against the infection by recognizing exogenous and endogenous 65 kd hsp on infected cells and producing cytokines such as gamma
IFN
. The hsp-specific T cells respond quickly to antigenically diverse pathogens before antigen-specific T cells expand clonally, and they play a role in covering the gap between the phagocytic system and highly evolved immune response. 65 kd hsp-specific T cells play important roles not only in host defense mechanism against infection with various pathogens but also in induction of auto-immune disease. Both 65 kd hsp-specific gamma delta T cells and 65 kd hsp-specific alpha beta T cells abrogate the unresponsiveness of the self-reactive alpha beta T cells and/or B cells by producing IL-2 and contribute to induction of
autoimmune disease
.
...
PMID:Regulatory role of heat shock protein-specific T cells in host defense. 151 51
Interferon-alpha (IFN-alpha) is currently used in the treatment of various malignant tumours. Development of different autoimmune disorders has been reported in some patients during
IFN
-alpha therapy. Systemic lupus erythematosus (SLE) after treatment with
IFN
-alpha has not been described, although a majority of SLE patients have demonstrable serum levels of
IFN
-alpha, which correlate with disease activity and have been suggested to be of pathogenetic significance. In this paper we describe a patient with a malignant carcinoid tumour who developed a SLE-like syndrome during treatment with leucocyte
IFN
-alpha. The patient developed myalgia and low grade arthritis in multiple joints together with a high titre of antinuclear antibodies (ANA) and anti-dsDNA antibodies. After the treatment was stopped, the symptoms subsided although a moderate ANA titre persisted. However, the tumour continued to regress despite cessation of
IFN
-alpha therapy. During a short course with recombinant
IFN
-alpha the syndrome relapsed, supporting the concept that the SLE syndrome was precipitated by
IFN
-alpha. A connection between
IFN
-alpha treatment, the induced
autoimmune disorder
and regression of the carcinoid tumour is suggested.
...
PMID:Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. 169 Feb 58
Several previous reports suggest an association between treatment of patients with interferon-alpha (IFN-alpha) and development of autoantibodies and
autoimmune disease
. We here summarize the experience from a group of 135 patients with midgut carcinoid tumors treated with natural leukocyte
IFN
-alpha or recombinant
IFN
-alpha (rIFN-alpha). An unusual high incidence of antimicrosomal antibodies (MsAb) or anti-thyroglobulin antibodies (TgAb) and thyroid disease manifested as hyperthyroidism, hypothyroidism or a biphasic Hashimoto-like disease was seen, with female predominance. The incidence of antinuclear antibodies (ANA) was also increased, but equally in both sexes. Antibodies to parietal cells were found in 5 cases and 4 patients with pernicious anemia were detected. Two patients developed vasculitis of leukocytoclastic type and one a syndrome resembling systemic lupus erythematosus. Some patients treated with rIFN-alpha develop anti-
IFN
antibodies. Such antibodies may also be autoantibodies reacting with autologous
IFN
-alpha. They can neutralize the biologic activity of administrated
IFN
preparation and cause therapeutic failure. The implications of the various autoimmune manifestations during
IFN
-alpha treatment are discussed.
...
PMID:Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. 185 11
The occurrence of
autoimmune disease
in patients receiving alpha-interferon (alpha-IFN) therapy has been reported in several studies; these include autoimmune thyroiditis, thrombocytopenia, anemia, exacerbation of psoriasis, and the occurrence of sarcoidosis. The primary mechanism presumably is the emergence of autoantibodies to various structural proteins or receptors. Two studies have recently shown that a significant percentage of patients treated with recombinant alpha-interferon (r alpha-IFN) do form autoantibodies. The authors report six additional cases of development or exacerbation of autoimmune phenomena in patients receiving alpha-
IFN
therapy. Five of these patients developed symmetric polyarthropathies and the sixth had thyroiditis. The presence of a history of underlying
autoimmune disease
or baseline serologic abnormalities in five of these patients, including the patient who developed thyroiditis, suggests that alpha-
IFN
treatment can lead to the exacerbation of an underlying subclinical autoimmune process.
...
PMID:Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. 234 7
All healthy subjects have the capacity to produce autoantibodies markedly similar to those seen in
autoimmune disease
. This capacity may be activated by viruses, through the release of
IFN
or other mechanisms.
Autoimmune disease
can be induced or enhanced by interferons in mice and in humans. Circulating IFNs are very frequent in patients with autoimmune diseases and may participate in the mediation of several clinical and immunologic manifestations.
IFN
-induced aberrant HLA-DR expression is common on epithelial cells of target organs of many autoimmune diseases; it may present autoantigen to T-cells and initiate a cycle of self-perpetuating autoimmunity. Interaction of
IFN
with other lymphokines (TNF, interleukin 1, etc.) may contribute to disease development. Further understanding of the role of lymphokines in autoimmunity may provide the basis for specific therapy in the future.
...
PMID:Lymphokines in autoimmunity--roles of interferons in systemic lupus erythematosus and other autoimmune disorders. 246 83
In both thyroid autoimmune diseases Graves' and Hashimoto's thyroiditis, the epithelial thyroid follicular cells (TFC) have been shown to express HLA class II molecules, and can restimulate autoreactive T cells cloned from the diseased tissue. This aberrant class II expression is important in the mechanism of perpetuation of the disease process, therefore we have compared the effect of interferon gamma (
IFN
gamma) and tumour necrosis factor (TNF alpha) on the HLA-DR alpha mRNA expression of thyroid follicular cells derived from Graves' disease (GD) and a non
autoimmune disease
, non toxic goitre (NTG). Our results indicate that TNF alpha synergises with
IFN
gamma in the induction of HLA class II mRNA. There was no consistent difference in DR alpha mRNA expression between the GD and NTG thyroid follicular cell preparations in response to induction by a combination of these lymphokines at various concentrations. Our data suggest that the differences in the level of expression of class II molecules observed in vivo in Graves' disease and non toxic goitre, which is much higher in the former, is probably due to local release of lymphokines by infiltrating T lymphocytes, although other factors may be involved.
...
PMID:Tumour necrosis factor synergises with gamma interferon on the induction of mRNA for DR alpha chain on thyrocytes from Graves' disease and non toxic goitre. 251 29
Among 49 patients with carcinoid tumors given long term therapy (mean, 8 months; range, 3-36) with human leukocyte-derived interferon-alpha (huLe-
IFN
alpha), hypothyroidism occurred in 5 and thyrotoxicosis in 2. Antibodies against thyroid microsomal antigen and/or thyroglobulin were found in 13 patients. In 7 of these, 3 of whom developed hypothyroidism, the antibodies appeared after the start of therapy. During treatment, an increase in the proportions of circulating activated surface HLA-DR-positive T-helper and T-suppressor cells occurred after 3-4 days, and the proportions remained elevated at 3 and 6 months. Incubation of T cells of normal individuals in vitro with the huLe-
IFN
alpha preparation induced a rise in activated T-helper and T-suppressor cells. This effect was mimicked by recombinant
IFN
gamma (r-
IFN
gamma), but not by r-
IFN
alpha. Further, the huLe-
IFN
alpha preparation employed induced HLA-DR expression on human thyroid cells in tissue culture as did r-
IFN
gamma, but not r-
IFN
alpha, suggesting the presence of bioactive
IFN
gamma in the huLe-
IFN
alpha preparation. The results demonstrate that thyroid
autoimmune disease
can occur as a side-effect of treatment with huLe-
IFN
alpha and suggest that IFNs may play important regulatory roles, at both the effector and target cell levels, in the development of human autoimmune disorders.
...
PMID:Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. 294 10
NK cells may be important in the elimination of cells infected by virus, in the regulation of antibody production, and in tissue destruction. The significance of NK cells in rheumatic disorders is unknown, but NK cells and NK-like cells have been found in the peripheral blood and synovial tissues of patients with
autoimmune disease
. In particular, defects in NK cell activity have been reported in SLE, RA, PSS and SS. Of these diseases, SLE appears to be the best characterized with obvious abnormalities in NK cell numbers, impaired cytotoxicity of individual NK cells, decreased release of cytotoxic factors, deranged
IFN
modulation of the NK cell, and associated abnormalities in the IL-2 system. The association of these abnormalities with the underlying disease process is currently under investigation.
...
PMID:Natural killer cells in connective tissue disorders. 390 53
Seeking common abnormalities in mice genetically predisposed to lupus-like
autoimmune disease
, we investigated (1) the ontogeny of Ia antigens (I-A/I-E) on the surfaces of resident peritoneal macrophages (rpM phi) of lupus and normal mice, (2) spontaneous and lectin-induced in vitro production of M phi-stimulating factors (interferon,
IFN
; M phi-activating factor, MAF; M phi-Ia-inducing/recruiting factor, MIRF), and (3) responses of rpM phi from such animals to Ia-inducing signals. Indirect immunofluorescence techniques showed that Ia+ rpM phi increased numerically during the life spans of MRL/Mp lpr/lpr, while no such increase was observed in age-matched non-lpr MRL/Mp +/+ or (MRL/Mp lpr/lpr X MRL/Mp +/+)F1 hybrid mice. However, neonatal thymectomy, which prevents lymphoproliferation and
autoimmune disease
in MRL/Mp lpr/lpr mice, had no effect on this enhanced M phi I-A/I-E expression. NZB mice developed a similar increase with age, whereas BXSB and (NZB X NZW)F1 lupus mice, like immunologically normal controls, had low numbers of I-A/I-E+ rpM phi. Cultured splenocytes of lupus mice, including those with high percentages of I-A/I-E+ rpM phi, did not spontaneously (in the absence of mitogens) elaborate MIRF, MAF, or
IFN
activity. Furthermore, concanavalin A-stimulated splenocytes from lupus mice, particularly strains with early
autoimmune disease
manifestations [MRL/Mp lpr/lpr, male BXSB, and female (NZB X NZW)F1] produced levels of these lymphokines that were lower than normal controls. MRL/Mp lpr/lpr and NZB rpM phi, when stimulated in vitro with the supernatant of a MIRF-producing T cell hybridoma, did not hyperrespond. Our study shows that increased I-A/I-E+ rpM phi occur in some, but not all, lupus mice and this increase does not correlate with increased spontaneous or mitogen-induced production of M phi-stimulating lymphokines nor with hyperresponsiveness to Ia-inducing signals.
...
PMID:Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. 620 80
1
2
3
4
5
6
7
8
9
10
Next >>